Oppenheimer Reaffirms Outperform Rating for Harmony Biosciences (NASDAQ:HRMY)
Oppenheimer reiterated their outperform rating on shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $59.00 price target on the stock, up from their previous price target of $56.00. A number of other research firms also recently issued reports on HRMY. […]
More Stories
10 Fun Things To Do Online When Bored
It’s a lot easier to find ourselves in a state of boredom than it should be. After all, you’re very...
Voya Investment Management LLC Sells 514 Shares of OSI Systems, Inc. (NASDAQ:OSIS)
Voya Investment Management LLC decreased its holdings in shares of OSI Systems, Inc. (NASDAQ:OSIS – Free Report) by 9.7% in...
Trump Announces ‘Full And Comprehensive’ Trade Agreement With UK
By Chris Summers President Donald Trump said on Thursday that a “full and comprehensive” trade deal has been agreed with...
Police Arrest Pro-Palestinian Protesters Occupying Columbia University Library
By Rachel Acenas Multiple people were arrested on May 7 during pro-Palestinian demonstrations at Columbia University in New York. Dozens...
Tudor Investment Corp ET AL Sells 14,940 Shares of Independent Bank Corp. (NASDAQ:INDB)
Tudor Investment Corp ET AL lowered its stake in shares of Independent Bank Corp. (NASDAQ:INDB – Free Report) by 54.9%...
The Manufacturers Life Insurance Company Buys 3,981 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)
The Manufacturers Life Insurance Company boosted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 12.7%...